Ken Griffin Ngm Biopharmaceuticals Inc Put Options Transaction History

Citadel Advisors LLC

6 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q1 2024 May 15, 2024	SELL	$1.17 - $1.92 $117 - $192	-100 Reduced 33.33%	200 $0
Q3 2023 Nov 14, 2023	SELL	$1.05 - $3.37 $945 - $3,033	-900 Reduced 75.0%	300 $0
Q2 2023 Aug 14, 2023	BUY	$2.44 - $4.53 $2,684 - $4,983	1,100 Added 1100.0%	1,200 $3,000
Q1 2023 May 15, 2023	SELL	$3.72 - $5.4 $1,860 - $2,700	-500 Reduced 83.33%	100 $0
Q4 2022 Feb 14, 2023	SELL	$3.41 - $12.93 $78,089 - $296,097	-22,900 Reduced 97.45%	600 $3,000
Q3 2022 Nov 14, 2022	BUY	$12.59 - $17.67 $295,865 - $415,245	23,500 New	23,500 $307,000

2.6M

300

Ticker NGM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 80,365,904
Description
NGM Biopharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of novel therapeutics to treat liver and metabolic diseases, retinal diseases, and cancer. The company's product candidates include Aldafermin, an engineered analog of human hormone fibroblast growth factor 19, which is in Phase IIb clinical trial...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.